{"id": "1349730235776831496", "creation": 1610635739.0, "user_id": "19642657", "social_network": "twitter", "nsfw": false, "request": ["b26b9dbc-1c5a-4cd3-a3a6-c2f5a51ad0fc", "6701c9aa-27fd-4cef-822d-72fe0c43583a"], "metrics": {"b26b9dbc-1c5a-4cd3-a3a6-c2f5a51ad0fc": {"retweet_count": 0, "reply_count": 0, "like_count": 4, "quote_count": 0}, "6701c9aa-27fd-4cef-822d-72fe0c43583a": {"retweet_count": 0, "reply_count": 0, "like_count": 4, "quote_count": 0}}, "text": "Our weekly newsletter is out!\u2611\ufe0f\n\nThis week: EuropaBio's response to the revision of the #EU legislation on #children &amp; #rarediseases medicines; #DSM &amp; #TUDelft: an #ArtificialIntelligence Lab; #AstraZeneca &amp; the authorisation of its #COVID19 #vaccine!\n\n\u27a1\ufe0fhttps://t.co/1ZbvEk4vgq https://t.co/kHWZzj1F1k", "first_save": 1634559108.199414, "hashtags": ["#EU", "#CHILDREN", "#RAREDISEASES", "#DSM", "#TUDELFT", "#ARTIFICIALINTELLIGENCE", "#ASTRAZENECA", "#COVID19", "#VACCINE"]}